\
&
Contact us
\
&
Contact us
Published on | 5 years ago
Programmes COST COSTThe collection deadline of the COST Open Call 2020 (OC-2020-1) has been extended to Friday 13 November 12:00 CET (noon).
This decision has been taken in acknowledgement of the many challenges faced by prospective applicants throughout the year due to the COVID-19 pandemic. This Open Call marks the last occasion under Horizon 2020 for prospective COST Action networks to apply for funding.
For the full press release click here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Advanced Digital Skills Deployment: Best use of technologies European Digital Innovation Hubs
A new wave of calls under the Digital Europe programme is now open for submission. The Commission seeks project proposals for the following topics: AI Continent calls Health: Data ingestion capacities and data services for the European Genomic Data Infrastructure in the European Health Data Space: data tools Health: Data ingestion capacities a... read more
Security Digital, Industry & Space Cybersecurity
The European Commission has opened a call for evidence to shape the future EU Quantum Act, expected to be adopted in 2026. This initiative aims to enhance research, industrial capacity, and supply chain resilience in quantum technologies. The call for contributions is open to a wide range of stakeholders, including Member State authorities, EU age... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
